Abstract
By administering immune checkpoint inhibitors in combination with bevacizumab to patients with advanced colorectal cancer with MSS/pMMR disease for whom first-line treatment failed, not only did the patients' prognosis improve, but the adverse drug reactions were also safe and controllable.
Introduction
Colorectal cancer (CRC) remains a significant global health challenge. For patients with advanced disease who fail first-line treatment, options are often limited to toxic chemotherapy regimens. A major hurdle in immunotherapy is that approximately 95% of metastatic CRC cases are microsatellite stable or proficient mismatch repair (MSS/pMMR). These are considered "cold" tumors because they have low levels of immune cell infiltration and a low mutational burden, making them notoriously resistant to immune checkpoint inhibitors (ICIs) like PD-1 blockers. This study investigates whether adding the anti-angiogenic drug Bevacizumab can remodel this hostile tumor microenvironment (TME) to make ICIs effective in a second-line setting.
Methods
The researchers conducted a prospective study involving 110 patients with MSS/pMMR advanced colorectal cancer who had failed first-line therapy.
- Experimental Group (n=60): Received Sintilimab (PD-1 inhibitor) plus Bevacizumab.
- Control Group (n=50): Received the standard FOLFIRI chemotherapy regimen plus Bevacizumab.
The team used immunohistochemistry (IHC) to score three specific cell types before and after treatment: CD8+ T lymphocytes (the "soldiers" of the immune system), tumor-associated macrophages (TAMs), and cancer-associated fibroblasts (CAFs).
Remodeling the "Cold" TME
The most significant finding was that the Sintilimab + Bevacizumab combination successfully altered the TME. Post-treatment, the experimental group showed a statistically significant increase in CD8+ T cells and a decrease in immunosuppressive TAMs and CAFs. This suggests that Bevacizumab "normalizes" tumor vessels, reducing high interstitial pressure and allowing immune cells to penetrate the previously "cold" tumor mass.
Clinical Results and Efficacy
The experimental group outperformed the control group across nearly all clinical metrics measured by RECIST 1.1 criteria:
- Median Progression-Free Survival (mPFS): 5 months vs. 4 months ($P < 0.05$).
- Objective Response Rate (ORR): 26.7% vs. 10.0% ($P < 0.05$).
- Disease Control Rate (DCR): 46.7% vs. 30.0%.
Safety and Prognostic Factors
Critically, the immunotherapy combination did not result in a higher rate of adverse events compared to the chemotherapy group, suggesting it is a viable, less toxic alternative for second-line therapy. Through a Cox proportional hazards model, the authors identified that age (≤60 years) and male gender were independent factors associated with better treatment responses in this specific cohort.
Limitations and Future Work
While promising, the study was a single-center trial with a relatively small sample size (110 patients) and limited follow-up duration for overall survival data. The researchers call for large-scale, multicenter randomized controlled trials to provide more robust evidence and further explore why younger male patients responded better, potentially leading to more personalized treatment protocols for MSS/pMMR colorectal cancer.
Summary updated